Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents Academic Article uri icon

Overview

MeSH Major

  • Angioplasty, Balloon, Coronary
  • Consumer Product Safety
  • Paclitaxel
  • Registries
  • Sirolimus
  • Stents

abstract

  • Compared with on-label use, off-label use of drug-eluting stents is associated with a higher rate of adverse outcomes during the index admission and at 1 year. Stent thrombosis occurred predominantly in patients who underwent off-label drug-eluting stent implantation. Clinicians should be cautious about extrapolating the benefits of drug-eluting stents over bare-metal stents observed in randomized clinical trials to higher-risk clinical settings that have not been assessed.

publication date

  • May 9, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1001/jama.297.18.2001

PubMed ID

  • 17488965

Additional Document Info

start page

  • 2001

end page

  • 9

volume

  • 297

number

  • 18